Sage Makes Deep Cuts, Axing 53% Of The Workforce, As It Reins In Zulresso
The company will cut 340 positions, primarily affecting Zulresso commercial operations, to save $170m, after announcing it will need to run new trials to support the regulatory plan for zuranolone.
You may also be interested in...
The companies reported positive Phase III data in postpartum depression, a market opportunity of up to half a million women in the US with a condition that remains underdiagnosed.
The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.